For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Sugen Incorporated

USPTO Granted Patents = 157

CIPO Patents = 5

EPO Patents = 7

Forward Citations = 3,470

Loading Chart...

Loading Chart...

127 inventors (with patents filed for the assignee):

Peng Cho Tang (101 out of 118 patents)

Gerald McMahon (60 out of 65 patents)

Li Hsiang Sun (47 out of 91 patents)

4. Gregory D Plowman (19 out of 44 patents)

5. Klaus Peter Hirth (19 out of 22 patents)

6. Chung Chen Wei (17 out of 21 patents)

7. Laura Kay Shawver (17 out of 21 patents)

8. Congxin Liang (15 out of 42 patents)

9. Asaad S Nematalla (13 out of 15 patents)

10. Jingrong Jean Cui (12 out of 44 patents)

11. Aviv Gazit (10 out of 30 patents)

12. G Davis Harris, Jr (8 out of 12 patents)

13. Ping Huang (8 out of 16 patents)

14. Tomas Vojkovsky (8 out of 12 patents)

15. Marcel Koenig (8 out of 15 patents)

Core Competencies:

Protein Kinase Inhibitors

Indolinone Derivatives

Biomarkers

Cancer Therapy

Tyrosine Kinase Inhibitors

Aminoheteroaryl Compounds

Triazolo Compounds

Cyclooxygenase Inhibitors

Pharmaceutical Formulations

Cell Proliferative Disorders

Combinatorial Libraries

Angiogenesis Modulation

157 patents: Sort by Forward Citations

1. 7871786 - GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof (2011-01-18),

2. 7582756 - 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors (2009-09-01),

3. 7572924 - Pyrrole substituted 2-indolinone protein kinase inhibitors (2009-08-11),

4. 7439329 - GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof (2008-10-21),

5. 7320996 - Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer (2008-01-22),

6. 7256189 - 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors (2007-08-14),

7. 7250417 - Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors (2007-07-31),

8. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

9. 7217737 - Method and compositions for inhibiting cell proliferative disorders (2007-05-15),

10. 7214700 - (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors (2007-05-08),

11. 7211600 - [object Object] (2007-05-01),

12. 7202265 - Indolinone combinatorial libraries and related products and methods for the treatment of disease (2007-04-10),

13. 7189721 - Bicyclic protein kinase inhibitors (2007-03-13),

14. 7186832 - Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors (2007-03-06),

15. 7186716 - 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors (2007-03-06),

Sugen Incorporated is a multinational biotechnology company specializing in the research, development, and commercialization of innovative therapies for various diseases. With a strong focus on precision medicine and personalized treatment approaches, Sugen is committed to improving the lives of patients worldwide. Our dedicated team of scientists, researchers, and industry experts collaborate to deliver groundbreaking solutions that address unmet medical needs. Visit our website to learn more about our cutting-edge products, ongoing clinical trials, and our mission to advance healthcare through innovation.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

157 Patents

#10 in South San Francisco, CA

#559 in California

#2,445 in US

#5,100 in the World

South San Francisco, CA, United States of America

Sugen Incorporated

Forward Citations = 3,470

127 inventors:

Peng Cho Tang (101 out of 118 patents)

Gerald McMahon (60 out of 65 patents)

Li Hsiang Sun (47 out of 91 patents)

4. Gregory D Plowman (19 out of 44 patents)

5. Klaus Peter Hirth (19 out of 22 patents)

Please report any incorrect information to support@idiyas.com

Loading…